Special Issue "De Novo Drug Design for Emerging and Reemerging Viruses"
Deadline for manuscript submissions: 31 December 2022 | Viewed by 4464
Interests: viral-host interplay; SARS-CoV; influenza A virus; site-targeted antivirals
For emerging and re-emerging viruses that are zoonotic in origin, de novo drug design targeting viral proteins and viral life cycles provides an efficient approach to inhibit virus replication and therefore cure the disease. A greater understanding of the basic virology of these viruses, including virus entry, cellular receptors, virus–cell fusion, viral RNA or DNA synthesis and duplication, and virus assembly and release, has resulted in many successful antiviral drugs in the last 20 years. Computer-based drug design or high-throughput drug screening against Influenza virus, Hepatitis C, and HIV have generated effective drugs that are available in many countries clinically. The development of drugs against highly pathogenic viruses such as the Ebola Virus and SARS-CoV-2 is yet ongoing and should be encouraged more because a considerable number of patients are still suffering from these viruses.
Additionally, drugs targeting cellular factors and regulating host immune response have been found to have great potential in antiviral applications. So-called “host-targeting antivirals (HTA)” are meant to be a novel strategy for broad-spectrum antivirals.
This Special Issue is designed to provide an up-to-date review of the latest progress and technologies in de novo drug design (such drugs can be small molecular, peptides, antibodies, etc.) for emerging and re-emerging viruses targeting viral or host proteins based on their protein structures or their unique functions in the viral life cycle.
Prof. Dr. Ke Xu
Prof. Dr. Yu Chen
Dr. Li Zhou
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Viruses is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2400 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- antiviral drugs
- de-novo drug design
- emerging virus
- SARS-CoV 2